Anthem Biosciences IPO: The Bengaluru-based firm, Anthem Biosciences, has secured Rs 1,016 crore from anchor buyers forward of its upcoming Preliminary Public Providing (IPO), which opens for public subscription on July 14.
In response to the BSE web site, the corporate has allotted 1.78 crore fairness shares to 60 anchor buyers at Rs 570 per share, which is the higher finish of the IPO worth band.
Anthem Biosciences anchor ebook checklist
The anchor ebook noticed participation from a number of outstanding international and home institutional buyers. Right here is the checklist:
- Abu Dhabi Funding Authority
- Authorities Pension Fund International
- Eastspring Investments
- Amundi Funds
- PineBridge International Funds
- Société Générale
- HDFC MF
- ICICI Prudential MF
- Axis MF
- UTI MF
- Quant MF
- Motilal Oswal MF
Anthem Biosciences IPO: Value band, lot measurement, key particulars
This concern is a proposal on the market (OFS) by the corporate’s promoters, buyers and different personnel materials. Because of this the corporate won’t get any profit from this concern and it is going to be purely quite a lot of recommendation. Nonetheless, data like lot measurement and worth band has not been disclosed but.
Value band, lot measurement
The corporate has fastened the worth band between Rs 540 and Rs 570 per share. Buyers can apply for 26 shares in a single lot and multiples tons.
Monetary efficiency
The corporate reported income of Rs 1,844 crore in FY25, a 30 per cent year-on-year enhance in comparison with Rs 1,419 crore in FY24. Whereas its revenue after tax (PAT) rose by 23 per cent to Rs 451 crore throughout the identical interval.
Listed rivals
The corporate has a number of listed trade friends, a few of that are leaders within the sector, together with Sai Life Sciences Restricted, Syngene Worldwide, Suven Life Sciences and Divi’s Laboratories.
BRLMs, registrar particulars
JM Monetary, Citigroup International Markets India, JP Morgan India, and Nomura Monetary Advisory and Securities (India) are performing because the book-running lead managers for the IPO. The corporate has appointed Kfin Applied sciences Restricted as registrar for the problems.
About Anthem Bioscience do?
Based in 2006, Anthem Biosciences is a Contract Analysis, Growth, and Manufacturing Organisation (CRDMO) targeted on innovation and expertise. The corporate operates throughout your entire pharmaceutical worth chain, together with drug discovery, growth, and manufacturing. It additionally produces and markets advanced fermentation-based Lively Pharmaceutical Components (APIs) resembling probiotics, enzymes, peptides, dietary actives, vitamin analogues, and biosimilars.
